What began at our inaugural forum in 2024 has since taken shape across the field. SOPHiA GENETICS and the Memorial Sloan Kettering Cancer Center (MSK) return to ASCO to convene leading voices in precision oncology, this time with a singular focus: the liquid biopsy revolution. 

This forum traces the journey from a pioneering academic-industry collaboration with MSK to a global movement reshaping how cancer is detected, monitored, and treated. 

Topics:

• From One Lab to the World: Liquid Biopsy as a Leapfrog Technology
• The Power of the Network in Expanding Access to Advanced NGS LBx
• Strategic Partnerships: The Engine Drivers
• Leading Advances In Precision Oncology With Open Innovation

Speakers:

• Bob T. Li, MD, PhD, MPH – Senior Vice President, Global Head of Medical Affairs, Oncology, AstraZeneca
• Pedram Razavi, MD, PhD – Director, Liquid Biopsy and Cancer Genomics & MSK Biomarker Development Program, Memorial Sloan Kettering Cancer Center
• Kojo Elenitoba-Johnson, MD – Chair of the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
• Dale Muzzey – Chief Scientific Officer, Myriad Genetics
• John Longshore, PhD, FACMG – Head of Scientific Affairs Global Oncology Diagnostics, AstraZeneca
• Nicola Normanno, MD – Scientific Director, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”
• Lou Welebob – Senior Vice President of BioPharma Companion Diagnostics, Myriad Genetics
• Ross Muken – President, SOPHiA GENETICS
• Philippe Menu, MD, PhD – EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS
• Jess Lambe - Vice President & Managing Director, BioPharma Business Development, SOPHiA

Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21^st.

Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.

You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.

Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU

The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.

Reserve your spot today!

El GENOMiCS INSIGHTS Day Panama se llevará a cabo el próximo 30 de julio, en el restaurante Maito. Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica.   Durante la jornada abordaremos temas clave como la transformación del diagnóstico genómico en Latinoamérica, las nuevas posibilidades clínicas de la biopsia líquida y experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™.   Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región.   A continuación, encontrará la agenda preliminar del evento.

What: SOPHiA GENETICS Exclusive Networking event

Where: Restaurante Maito

Date: 30 de julio

Time: 18h00-21h:00

Agenda

Why Attend?

Discover SOPHiA DDM™ – One platform, universally compatible, endless possibilities

Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders

Connect with your peers

Enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform.

Discuss

Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.

10 June 2026 I 15:00 - 17:00 GST | 7:00 - 9:00 EDT

Join us for an exclusive virtual event bringing together leading oncology experts, healthcare decision-makers, pharmaceutical partners, policy representatives, and key opinion leaders from across the Middle East region.

This high-level session will explore the future of precision medicine and the evolving role of liquid biopsy in transforming cancer care delivery and genomic testing strategies.

At the center of the discussion is the collaboration between SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center, showcasing the successful decentralization of MSK’s renowned genomic assay, MSK-ACCESS™, powered with SOPHiA DDM™ for liquid biopsy applications.

The event will also feature real-world implementation examples and regional perspectives from our local users at M42, an Abu Dhabi-based global healthcare leader, highlighting innovation, scalability, and impact in precision oncology.

Meet our world class line-up of speakers

The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.

We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.

Key Discussion Points:

• Decentralizing MSK-ACCESS® – Challenges and solutions for ensuring analytical accuracy, managing site variability, and optimizing workflows.
• Performance & Validation – How the SOPHiA DDM™ Platform maintains high concordance through advanced analytics, noise reduction, and standardized wet-lab processes.
• Real-World Adoption – Leah Thompson, MB (ASCP)CM shares insights on assay verification, workflow efficiency, and the ease of use in routine lab operations.

Learning Objectives:

• Understand the Challenges of Decentralization – Learn about the complexities involved in decentralizing MSK-ACCESS® and how the SOPHiA DDM™ Platform addresses key hurdles such as analytical accuracy, wet-lab standardization, and noise reduction.
• Evaluate Performance and Real-World Verification – Gain insights into the internal verification study results and real-world data from seven early adopter sites, demonstrating high analytical concordance between the decentralized and single-site versions of MSK-ACCESS®
• Explore Ease of Adoption and Workflow Efficiency – Understand how MSK-ACCESS® powered with SOPHiA DDM™ offers a streamlined workflow, reliable data quality, and a straightforward implementation process for laboratories.

July 8, 2026 | 1:00PM SGT

Liquid biopsy (LBx) has emerged as a non-invasive genomic profiling approach to guide decision-making and to monitor resistance in cancer, especially when access to tumor tissue is limited. However, one of the key challenges of LBx is distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants, which can occur in biologically relevant genes and confound variant interpretation. In this webinar, Dr. Keller and Dr. Fares (IUCT Oncopole, France) will explore real-world cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform decisions. The decentralized liquid biopsy solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations.

By attending this session, you will gain:

• Practical insights into the clinical utility of liquid biopsy
• An understanding of how CH confounds variant interpretation
• Real-world examples of how matched tumor-normal analysis helps inform decision-making

June 3, 2026 | 1:00PM SGT

Clinical Genomics at MSK​
Michael Berger, Ph.D​
Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, MSKCC​

Dr. Berger’s session will explore the development of MSK-IMPACT and MSK-ACCESS, MSK’s comprehensive genomic profiling andcfDNA analysis programs. These initiatives address the need for large-scale molecular profiling across diverse tumor types. A keyfocus will be the role of matched tumor-normal sequencing in reducing biological false positives, ensuring true somatic variantsare accurately identified while enabling seamless integration of germline analysis. Dr. Berger will also discuss how SOPHiAGENETICS has become a key collaborator, empowering MSK to expand the accessibility of precision oncology globally throughscalable, cloud-based solutions.​

Advancing Precision Oncology with a Matched Tumor-Normal Approach: Insights from the Clinic ​
Anita Bowman, M.S,​
Associate Director of Clinical Bioinformatics, MSKCC​

Anita Bowman will delve into the clinical applications of MSK-IMPACT and MSK-ACCESS at MSK, illustrating how thesetechnologies meet the personalized needs of patients. Through real-world case studies, she will showcase how a matchedtumor-normal approach has enhanced diagnosis and treatment planning. This methodology not only minimizes false positivesbut also identifies clonal hematopoiesis of indeterminate potential (CHIP) and resistance mechanisms, improving precision intreatment strategies.​

Learning Objectives​

• Understand the evolution and unique features of MSK’s genomic profiling programs (MSK-IMPACT and MSK-ACCESS) andtheir role in advancing precision oncology.​
• Explore the critical benefits of matched tumor-normal sequencing in reducing biological false positives, enabling accuratesomatic variant identification, and enhancing germline analysis.​
• Analyze real clinical cases demonstrating how MSK’s genomic technologies inform decision-making.

June 24, 2026 | 1:00PM SGT

• Florian Klemm, MD, PhD – Technical Product Manager, SOPHiA GENETICS​
• Ryan Demers, MSc – Global Diagnostics Director, Lung and Liquid Biopsy Strategy, AstraZeneca​
• Persephone du Parcq, MSc, PGDip, - Deputy Operations Lead, Synnovis

MSK-ACCESS® powered with SOPHiA DDM™ offers an innovative and decentralized solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform. This application aims to address the global inequalities in comprehensive cancer care.​

Watch to hear about the collaborative efforts of SOPHiA GENETICS and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™. In this session, you will​

• Learn about the decentralized approach, technology, and the analytical performance of this liquid biopsy application.​
• Explore the journey of creating a global network for liquid biopsy testing, including efforts to reach underserved regions where access is limited.​
• Gain insights from the first hands-on experience with MSK-ACCESS® powered with SOPHiA DDM™ from one of the early-access healthcare institutions.​

July 15, 2026 | 1:00 PM SGT

Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers.​ In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay. ​

Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.

In this session you will:​

• Discover how the SOPHiA GENETICS decentralised approach and advanced analytics enables scalable, robust, and reproducible liquid biopsy testing, through its decentralized approach, supported by large-scale evidence generation studies across local deployments.​
• Gain insights into the clinical impact and utility of adopting MSK-ACCESS® powered with SOPHiA DDM™, and how it improves access and outcomes for cancer patients.​
• Explore how decentralized testing strategies support late-stage pharmaceutical development and drive commercial success in precision medicine.​

SOPHiA GENETICS and Myriad Genetics have joined forces in a unique partnership combining Myriad’s centralized CDx and regulatory expertise with SOPHiA GENETICS’ decentralized, data-driven platform.

In this engager we explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine. Attendees will:

• Discover SOPHiA GENETICS’ and Myriad Genetics’ first-of-its kind CDx partnership model to unlock scale, regulatory compliance, and access to precision diagnostics and therapies.
• Gain insights into what a co-development strategy for CTA and CDx looks like in practice and how it enables simultaneous development and deployment at a central lab.
• Understand how Pharma-Diagnostics collaborations can support late-stage clinical development through commercialization.

Topics:

• The Hybrid CDx Model: A New Paradigm for Pharma Partnerships
• The Business Structure Behind SOPHiA GENETICS and Myriad Genetics Alliance
• Co-Developing a CTA-CDx: What Does it Look Like in Practice?
• From Single-Site CDx to a Global Distributed Kit: Scaling with the SOPHiA GENETICS Vision
• Going Beyond a Single Test: Expanding Myriad Genetics’ Portfolio
• Panel Discussion: Is a Hybrid Model the Future?

Speakers:

• Kristina McGuire – Executive Director & Head, Precision Medicine Laboratory Operations & Companion Diagnostics, Regeneron
• Lou Welebob – Senior Vice President of BioPharma Companion Diagnostics, Myriad Genetics
• Jess Lambe - Vice President & Managing Director, BioPharma Business Development, SOPHiA
• Vern Geckler – Senior Director, Alliance Management, Myriad Genetics
• Julien Pontis - Head of CDx & Clinical Diagnostics, SOPHiA GENETICS
• Drew Gibbs – Vice President, Business Development, Myriad Genetics
• Yves Serroen - Director, BioPharma Business Development, SOPHiA GENETICS
• Janni Mirosevich – Senior Director, BioPharma Business Development, SOPHiA GENETICS
• Dale Muzzey – Chief Scientific Officer, Myriad Genetics
• Jonathan Beer – Senior Director, Precision Medicine, Bristol Myers Squibb
• Brian Baker – Executive Director, Regulatory Affairs, In Vitro Diagnostics, Regeneron
• Michael Senior – Senior Director, Diagnostic Partnerships, Oncology Business Unit, AstraZeneca